United States-based Momenta Pharmaceuticals and United States-based Mylan have revealed plans to start a pivotal clinical study of a biosimilar to Regeneron's eye drug Eylea (aflibercept), it was reported yesterday.

Both firms are planning a development strategy for M710, a proposed biosimilar to Eylea injection. The partnership is planning to start a clinical trial in patients in the first half of this year.

The randomised, double-blind, active-control and multi-centre trial will recruit patients with diabetic macular oedema to compare the safety, efficacy and immunogenicity of M710 with Eylea.